CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023

Rhea-AI Summary

CVRx, Inc. plans to release its fourth quarter and full year 2022 financial results after market close on January 26, 2023. A conference call will follow at 5:30 p.m. Eastern Time to discuss the results, which will be available via webcast. CVRx focuses on innovative neuromodulation solutions for cardiovascular diseases, specifically the Barostim device, the first FDA-approved technology using neuromodulation to treat heart failure symptoms. Barostim has received FDA Breakthrough Device designation and is CE Mark approved for additional indications.

Positive

• FDA-approved Barostim device improves heart failure symptoms.
• Barostim received FDA Breakthrough Device designation.
• CE Mark approval for heart failure and resistant hypertension in EEA.

Negative

• None.

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2022 financial and operating results after market close on Thursday, January 26, 2023. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d5cu7e7x.To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:

Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com

FAQ

What date will CVRx release its financial results?

CVRx will release its financial results on January 26, 2023.

What is Barostim and how does it work?

Barostim is an FDA-approved implantable device that uses neuromodulation to reduce heart failure symptoms by restoring balance to the autonomic nervous system.

When is the CVRx conference call scheduled?

The CVRx conference call is scheduled for January 26, 2023, at 5:30 p.m. Eastern Time.

How can I listen to the CVRx conference call?

The conference call can be listened to via webcast, and participants can also register to join by phone.